Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026)
Mereo BioPharma (MREO) reported Income from Continuing Operations of 6719000.0 for Q1 2026, up 47.86% year-over-year from 4544096.2 in Q1 2025, and up 8.6% quarter-over-quarter from 7351000.0 in Q4 2025.
Mereo BioPharma (MREO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has 4 years of Income from Continuing Operations data on file, last reported at 6719000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 6719000.0, up 47.86% year-over-year; the trailing twelve-month figure through Mar 2026 was 35710000.0 (up 24.33% YoY), and the FY2025 annual result was 41878000.0, up 3.18% from the prior year.
- Income from Continuing Operations rose to 6719000.0 in Q1 2026 per MREO's latest filing, from 7351000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1751000.0 in Q2 2023 and troughed at 15001000.0 in Q3 2024.
- A 4-year average of 9413923.08 and a median of 8951000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 599.89% in 2024, then soared 53.18% in 2025.
- A 4-year view of Income from Continuing Operations shows it stood at 10173000.0 in 2023, then surged by 30.74% to 7046000.0 in 2024, then decreased by 4.33% to 7351000.0 in 2025, then increased by 8.6% to 6719000.0 in 2026.
- Business Quant data shows MREO's Income from Continuing Operations at 6719000.0 in Q1 2026, 7351000.0 in Q4 2025, and 7024000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Mereo BioPharma | 252.49 Mn | 252.49 Mn | - | -6.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.72 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Sep 30, 2025 | -7.02 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -12.89 Mn |
| Dec 31, 2024 | -7.05 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -12.26 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -10.17 Mn |
| Sep 30, 2023 | -6.53 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -12.08 Mn |